Related Experiment Video
Updated: Jul 7, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[Pharmacogenetics in fluoropyrimidine chemotherapy]
Wataru Ichikawa1, Yasutsuna Sasaki
1Deptartment of Medical Oncology, International Cancer Center, Saitama Medical University.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 19, 2008
Summary
Pharmacogenetics research using candidate genes shows promise for predicting patient response to fluoropyrimidine treatments. However, prospective studies are needed to validate these biomarkers for clinical use.
Area of Science:
- Pharmacogenetics
- Oncology
- Clinical Pharmacology
Context:
- Candidate gene approaches have identified polymorphisms in the 5-fluorouracil pathway correlating with patient outcomes.
- Retrospective studies in small cohorts suggest potential predictive biomarkers for fluoropyrimidine therapy.
- Lack of prospective validation currently limits the clinical application of these candidate genes.
Purpose:
- To review the current status of pharmacogenetics in predicting clinical outcomes for fluoropyrimidine-treated patients.
- To highlight the limitations of the candidate gene approach for biomarker development.
- To advocate for comprehensive pathway and global approaches in future research.
Summary:
- Pharmacogenetic studies have explored candidate genes within the 5-fluorouracil pathway to predict treatment response, survival, and toxicity.
- While retrospective analyses show correlations, these findings require prospective confirmation before clinical implementation.
- The current candidate gene approach is insufficient for reliable clinical prediction.
Impact:
- Identifies the need for robust, prospective validation of pharmacogenetic biomarkers.
- Suggests future research directions utilizing pathway-wide and genome-wide approaches.
- Aims to improve the clinical utility of pharmacogenetics in optimizing fluoropyrimidine chemotherapy.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...